<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924402</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb13676-01</org_study_id>
    <nct_id>NCT02924402</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of intravenous (IV)&#xD;
      administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or&#xD;
      recommended dose (RD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will enroll two parallel disease groups in escalation: patients with non-CLL B cell malignancies and patients with CLL/SLL/Richter's Transformation. In expansion it will enroll DLBCL and FL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>B-cell Non-Hodgkins Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLL/SLL (Group CLL) Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLL/SLL (Group CLL) Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb13676</intervention_name>
    <description>Biological</description>
    <arm_group_label>CLL/SLL (Group CLL) Part A</arm_group_label>
    <arm_group_label>CLL/SLL (Group CLL) Part B</arm_group_label>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Expansion</arm_group_label>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Part A</arm_group_label>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL) Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Diagnosis of either Non-CLL B cell malignancy or CLL/SLL&#xD;
&#xD;
          -  Ineligible for or have exhausted standard therapeutic options and have relapsed or&#xD;
             refractory disease&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Fertile patients must agree to use highly effective contraception during and for 5&#xD;
             months (male patients) and 8 months (female patients) after last dose of XmAb13676&#xD;
&#xD;
          -  Able and willing to complete the entire study&#xD;
&#xD;
        Additional Patient Inclusion Criteria for the DLBCL Cohort (Expansion Phase)&#xD;
&#xD;
          1. Histologically confirmed diagnosis (specified by 2016 World Health Organization) of&#xD;
             DLBCL or transformed low-grade lymphoma with measurable disease&#xD;
&#xD;
          2. Patient must be refractory or have relapsed after 2 or more standard therapeutic&#xD;
             options, at least one of which must have included anti-CD20 antibody therapy.&#xD;
&#xD;
          3. Not a candidate for or refusing treatment with hematopoietic stem cell transplantation&#xD;
&#xD;
        Additional Patient Inclusion Criteria for the Follicular Lymphoma Cohort (Expansion Phase)&#xD;
&#xD;
          1. Diagnosis of follicular lymphoma Grades 1-3a&#xD;
&#xD;
          2. Patient must be ineligible for or have exhausted standard therapeutic options and have&#xD;
             had 2 or more prior systemic regimens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cytotoxic chemotherapy, radiotherapy, or immunotherapy including other anti-CD20&#xD;
             antibodies within 4 weeks, or small molecule or investigational agents within 6&#xD;
             elimination half-lives of the first dose of XmAb13676&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Failure to recover from Grade 3 or 4 toxicity from previous treatment&#xD;
&#xD;
          -  Multiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemia&#xD;
&#xD;
          -  Known intolerance to CD20 monoclonal antibody therapy&#xD;
&#xD;
          -  History of primary central nervous system lymphoma or neoplastic central nervous&#xD;
             system disease&#xD;
&#xD;
          -  Platelet count &lt; 50 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1.0 x 10^9/L&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening &gt; 3x&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &gt; 1.5 mg/dL unless prior diagnosis and documentation of ongoing hemolysis or&#xD;
             Gilbert's syndrome has been made)&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 50 40 mL/min&#xD;
&#xD;
          -  Active/uncontrolled autoimmune disease&#xD;
&#xD;
          -  Clinically significant cardiac/cardiovascular disease, or pulmonary compromise&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  History of stroke with the past year6 mos prior to study entry&#xD;
&#xD;
          -  History or evidence of a clinically unstable/uncontrollable disorder, condition or&#xD;
             disease other than primary malignancy, that in the opinion of the Investigator would&#xD;
             pose a risk to the patient safety or interfere with the study evaluation, procedures&#xD;
             or completion&#xD;
&#xD;
          -  Evidence of any serious bacterial, viral, parasitic or systemic fungal infections&#xD;
             within the 30 days prior to study entry&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus (HIV) or hepatitis C (HCV) antibodies&#xD;
             (unless HCV viral load test by PCR is negative)&#xD;
&#xD;
          -  Positive test for HbsAg, or positive test for HBcAb (unless serology is positive due&#xD;
             to recent intravenous immunoglobulin therapy). HBcAb positivity will be allowed if&#xD;
             HBsAb is present.&#xD;
&#xD;
          -  Patient is pregnant or breast feeding, or planning to become pregnant while enrolled&#xD;
             in the study, and 8 months after the last dose of study drug&#xD;
&#xD;
          -  Positive urine pregnancy test (ie, urine human chorionic gonadotropin) at screening&#xD;
&#xD;
          -  Live viral vaccine within 2 weeks of the first dose of XmAb13676&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raman Garcha, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director, Clinical Development, Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raman Garcha, MD</last_name>
    <phone>858-480-3660</phone>
    <phone_ext>660</phone_ext>
    <email>rgarcha@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phuong Lee</last_name>
    <phone>858-480-3115</phone>
    <phone_ext>215</phone_ext>
    <email>plee@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Young</last_name>
      <phone>904-953-9971</phone>
      <email>young.anna@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Brown</last_name>
      <phone>404-780-7965</phone>
      <email>Stacey.Brown@Northside.com</email>
    </contact>
    <contact_backup>
      <last_name>Melhem Solh, M.D</last_name>
      <phone>404-255-1930</phone>
      <email>msolh@bmtga.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tycel Phillips, MD</last_name>
      <phone>734-647-8901</phone>
      <email>tycelp@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstie Armstrong</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>209</phone_ext>
      <email>karmstrong@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Smith</last_name>
      <phone>330-471-8231</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center and James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meixiao Long, MD</last_name>
      <email>Meixiao.Long@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Rike</last_name>
      <phone>(614) 688-6559</phone>
      <email>Lindsey.Rike@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Wierda, MD</last_name>
      <email>wwierda@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Jeanne Lichty, RN</last_name>
      <phone>713-794-4683</phone>
      <email>jmlichty@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sairah Ahmed, MD</last_name>
      <email>SAhmed3s@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Morphey</last_name>
      <phone>713-792-8785</phone>
      <email>Alandry1@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UVA Health System, Division of Hematology &amp; Oncology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krish Patel, MD</last_name>
      <phone>206-215-2338</phone>
      <email>krish.patel@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Tenzin Tsomo</last_name>
      <phone>206-386-2831</phone>
      <email>Tenzin.Tsomo@swedish.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, MD</last_name>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Corinne Haioun</last_name>
      <phone>33 1 49 81 20 51</phone>
      <email>corinne.haioun@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette Dpt of Oncology/Hematology</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Schiano de Collela, MD</last_name>
      <phone>33 4 91 22 38 61</phone>
      <email>schianojm@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier, Hematologie Clinique St. Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Guillaume Cartron</last_name>
      <phone>33 4 67 33 26 45</phone>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Cogrel</last_name>
      <email>icolas.cogrel@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr. Frederic Peyrade</last_name>
      <phone>33 4 92 03 10 47</phone>
      <email>frederic.peyrade@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal Krimo Bouabdallah, MD</last_name>
      <phone>33 5 57 65 65 11</phone>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud, Service d'Hematologie</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Ghesquieres</last_name>
      <phone>33 4 78 86 43 37</phone>
      <email>herve.ghesquieres@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Herv√© Tilly</last_name>
      <phone>33 2 32 08 22 20</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic Yesbaert, MD</last_name>
      <phone>33 5 31 15 63 51</phone>
      <email>ysebaert.loic@iuct.oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Vincent Ribrag</last_name>
      <phone>33 1 42 11 58 20</phone>
      <email>Sabrine.SALHI@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>B-cell Prolymphocytic Leukemia</keyword>
  <keyword>Transformed Lymphoma</keyword>
  <keyword>Burkitt's Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Hairy Cell Leukemia</keyword>
  <keyword>Splenic Marginal Zone Lymphoma</keyword>
  <keyword>Waldenstrom's Macroglobulinemia</keyword>
  <keyword>Variant Hairy Cell Leukemia</keyword>
  <keyword>Splenic B-cell Lymphoma/Leukemia</keyword>
  <keyword>Lymphoplasmacytic Lymphoma</keyword>
  <keyword>Extranodal Marginal Zone Lymphoma (MALT)</keyword>
  <keyword>MALT Lymphoma</keyword>
  <keyword>Nodal Marginal Zone Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>In Situ Follicular Neoplasia</keyword>
  <keyword>Duodenal-type Follicular Lymphoma</keyword>
  <keyword>Large B-cell Lymphoma with IRF4 rearrangement</keyword>
  <keyword>Primary Cutaneous Follicle Center Lymphoma</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>T-cell/Histiocyte-Rich Large B-cell Lymphoma</keyword>
  <keyword>Primary Cutaneous DLBCL, leg type</keyword>
  <keyword>EBV-positive DLBCL, NOS</keyword>
  <keyword>EBV-positive Mucocutaneous Ulcer</keyword>
  <keyword>DLBCL Associated with Chronic Inflammation</keyword>
  <keyword>Lymphomatoid Granulomatosis</keyword>
  <keyword>Primary Mediastinal (Thymic) Large B-cell Lymphoma</keyword>
  <keyword>Intravascular Large B-cell Lymphoma</keyword>
  <keyword>ALK+ Large B-cell Lymphoma</keyword>
  <keyword>Plasmablastic Lymphoma</keyword>
  <keyword>Primary Effusion Lymphoma</keyword>
  <keyword>HHV8+ DLBCL</keyword>
  <keyword>Burkitt-like Lymphoma with 11q Aberration</keyword>
  <keyword>High-grade B-cell Lymphoma</keyword>
  <keyword>B-cell Lymphoma, unclassifiable</keyword>
  <keyword>Post-transplant Lymphoproliferative Disorder</keyword>
  <keyword>PTLD</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>High-grade Lymphoma</keyword>
  <keyword>Richter's Transformation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

